Evidence map›Paper›PMID 28545167›Full record

ArticleJournal of labelled compounds & radiopharmaceuticals2017

Synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-(methyl-d

Malliga R Iyer, Resat Cinar, Nathan J Coffey, Robert J Chorvat, George Kunos

Open access · greenAbstract read
In one paragraph

Article in Journal of labelled compounds & radiopharmaceuticals, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Malliga R IyerLaboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0002-0116-4619
Resat CinarLaboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.
Nathan J CoffeyLaboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.ORCID 0000-0002-9413-5533
Robert J ChorvatJenrin Discovery LLC, Chadds Ford, PA, USA.
George KunosLaboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA.
National Institutes of Health · USJenrin Discovery (United States) · US

Funding

Endocannabinoids And Energy HomeostasisZIAAA000350 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI KUNOS, GEORGE · 2009 to 2025
$28.4M
Intramural NIH HHS Z99 AA999999
6 · The paper itself

Abstract

JD5037 (1) is a potent and selective, peripherally acting inverse agonist of the cannabinoid (CB

Indexed as

AmidesChemistry Techniques, SyntheticDeuteriumModels, MolecularMolecular ConformationPyrazolesReceptor, Cannabinoid, CB1SulfonamidesAmidesDeuteriumJD5037PyrazolesReceptor, Cannabinoid, CB1SulfonamidesADMECB1RECPSA

Identifiers

PMID28545167
PMCPMC5568925
OpenAlexW2616998905

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.